Acetyl-l-carnitine Versus Placebo For Migraine Prophylaxis: A Randomized, Triple-blind, Crossover Study
Notes for this study:
||Attack duration, hours, mean (SD). Baseline: 11.3 (8.5) Placebo: 11.5 (8.9) Carnitine: 12.0 (8.7)
|Number of Subjects
||18-29, 30-44, 45-64
In a 12-week randomized, triple-blind, placebo-controlled crossover trial, 72 participants with frequent migraines took placebo or 1.5 g of acetyl-l-carnitine during the first week and 3 g for the rest of the 12 weeks before crossing over.
The primary outcome was days with moderate or severe headaches, and there wasn't a statistically significant difference between treatments for any headache-related measure. The placebo group saw significantly less depression, though the participants weren't particularly depressed.
There wasn't a notable difference in adverse events.